0.6695
1.49%
+0.0098
After Hours:
.6403
-0.0292
-4.36%
Evogene Ltd stock is currently priced at $0.6695, with a 24-hour trading volume of 22,959.
It has seen a +1.49% increased in the last 24 hours and a -15.57% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.663 pivot point. If it approaches the $0.6843 resistance level, significant changes may occur.
Previous Close:
$0.6597
Open:
$0.665
24h Volume:
22,959
Market Cap:
$33.89M
Revenue:
$5.64M
Net Income/Loss:
$-23.88M
P/E Ratio:
-1.2173
EPS:
-0.55
Net Cash Flow:
$-22.36M
1W Performance:
-2.26%
1M Performance:
-15.57%
6M Performance:
+42.42%
1Y Performance:
+15.55%
Evogene Ltd Stock (EVGN) Company Profile
Name
Evogene Ltd
Sector
Industry
Phone
972 8 931 1900
Address
13 Gad Feinstein Street, Park Rehovot PO Box 4173, Rehovot
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-08-21 | Initiated | ROTH Capital | Buy |
Jul-29-21 | Initiated | Aegis Capital | Buy |
Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
Zacks Investment Research
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Bears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' Now
Zacks Investment Research
Evogene Ltd Stock (EVGN) Financials Data
Evogene Ltd (EVGN) Revenue 2024
EVGN reported a revenue (TTM) of $5.64 million for the quarter ending December 31, 2023, a +236.72% rise year-over-year.
Evogene Ltd (EVGN) Net Income 2024
EVGN net income (TTM) was -$23.88 million for the quarter ending December 31, 2023, a +10.36% increase year-over-year.
Evogene Ltd (EVGN) Cash Flow 2024
EVGN recorded a free cash flow (TTM) of -$22.36 million for the quarter ending December 31, 2023, a +10.01% increase year-over-year.
Evogene Ltd (EVGN) Earnings per Share 2024
EVGN earnings per share (TTM) was -$0.53 for the quarter ending December 31, 2023, a +17.19% growth year-over-year.
About Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Cap:
|
Volume (24h):